<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-17M93MM4/8eff7875-b630-4e4f-9552-63e3452d82d7/HTML"><dcterms:extent>54 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-17M93MM4/3d56783a-5f56-438c-aea3-5c40783d55ea/PDF"><dcterms:extent>117 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-17M93MM4/cfb09445-22d2-4fa1-b21e-f57664d4e6b3/TEXT"><dcterms:extent>32 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-17M93MM4"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2008</dcterms:issued><dc:creator>Geršak, Borut</dc:creator><dc:creator>Preložnik-Zupan, Irena</dc:creator><dc:creator>Šoštarič, Maja</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">7 strani</dc:format><dc:format xml:lang="sl">letnik:77</dc:format><dc:format xml:lang="sl">str. 247-253</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:24203993</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-17M93MM4</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">Adverse Effects</dc:subject><dc:subject xml:lang="en">Antagonists And Inhibitors</dc:subject><dc:subject xml:lang="sl">antikoagulacijsko zdravljenje</dc:subject><dc:subject xml:lang="en">cardiovascular disease</dc:subject><dc:subject xml:lang="en">Chemically Induced</dc:subject><dc:subject xml:lang="en">Heart Diseases</dc:subject><dc:subject xml:lang="en">Heparin</dc:subject><dc:subject xml:lang="sl">kardiovaskularne bolezni</dc:subject><dc:subject xml:lang="sl">Srce, bolezni</dc:subject><dc:subject xml:lang="sl">srčne operacije</dc:subject><dc:subject xml:lang="en">Surgery</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">Thrombin</dc:subject><dc:subject xml:lang="en">Thrombocytopenia</dc:subject><dc:subject xml:lang="sl">Trombin</dc:subject><dc:subject xml:lang="sl">Trombocitopenija</dc:subject><dc:subject xml:lang="sl">zapleti</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Srčna operacija pri bolniku s heparinom povzročeno trombocitopenijo| Heparin induced thrombocytopenia and cardiac surgery|</dc:title><dc:description xml:lang="sl">Background Heparin induced thrombocytopenia (HIT) is a serious complication related to the heparin treatment and might lead to the life-threatening consequences such as arterial and venous thrombosis. The patient with HIT scheduled for cardiac surgery represents serious problem because heparin, mostcommon used anticoagulation drug during cardiac surgery, must be avoided. Conclusions From the results of the recent clinical studies it seems that direct thrombin inhibitors, especially bivalirudin represent an acceptable alternative to the heparin anticoagulation during the cardiac surgery</dc:description><dc:description xml:lang="sl">Izhodišča S heparinom povzročena trombocitopenija (heparin induced thrombocytopenia - HIT) je resen zaplet zdravljenja s heparinom, ki lahko vodido arterijskih in venskih tromboz. Poseben problem so bolniki s HIT, ki potrebujejo operacijo na srcu. Pri omenjenih bolnikih ne smemo uporabiti heparina kot antikoagulantno sredstvo med operacijo, ampak moramo izbrati drugo neheparinsko antikoagulantno zdravilo. Zaključki Ugotovitve kliničnih študij iz zadnjih let kažejo na to, da so zdravila iz skupine direktnih inhibitorjev trombina, še posebno bivalirudin, primerna kot antikoagulantno zdravilo med srčno operacijo</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-17M93MM4"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-17M93MM4" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-17M93MM4/3d56783a-5f56-438c-aea3-5c40783d55ea/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-17M93MM4/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-17M93MM4" /></ore:Aggregation></rdf:RDF>